Chen Bihua — SEC insider filings
SEC reporting owner CIK 1599214. 73 insider filings on record with FilingPulse; latest filed 2026-11-02.
Transaction summary — filings shown
Covers the 50 most recent of 73 filings on record, filed 2022-06-24 to 2026-11-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 125 legs across 29 filings — 27,201,280 shares, $435,405,058 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 25 legs across 10 filings — 19,459,827 shares, $67,002,758 total (shares × price as filed on priced legs).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 35.
- Largest priced transaction: purchase of 800,000 shares @ $50.00 ($40,000,000) in MoonLake Immunotherapeutics, filed 2023-07-05.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | — | 6 | 36 legs · 2,429,151 sh · $97,634,498 | 5 legs · 6,499,978 sh · $46,868,184 | — |
| Ambrx Biopharma Inc. (AMAM) | 10% owner | 4 | 11 legs · 10,965,823 sh · $114,106,979 | — | — |
| EyePoint, Inc. (EYPT) | — | 6 | 24 legs · 4,794,057 sh · $89,496,413 | 1 leg · 60,000 sh · $942,240 | — |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | — | 6 | 31 legs · 1,932,632 sh · $53,693,261 | 2 legs · 455,029 sh · $2,086,767 | — |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | Director, 10% owner | 5 | 3 legs · 2,400,000 sh · $24,000,000 | — | 17 |
| BRIGHT MINDS BIOSCIENCES INC. (DRUG) | — | 3 | 12 legs · 606,922 sh · $7,234,370 | 1 leg · 109,331 sh · $9,785,124 | — |
| Biomea Fusion, Inc. (BMEA) | — | 6 | 1 leg · 400,000 sh · $12,000,000 | — | 4 |
| Ambrx Biopharma, Inc. (AMAM) | 10% owner | 1 | 1 leg · 1,307,311 sh · $9,139,542 | — | — |
| BioAge Labs, Inc. (BIOA) | — | 1 | 1 leg · 450,000 sh · $8,100,000 | — | 2 |
| Helix Acquisition Corp. III (HLXC) | Chairperson and CEO, Director, 10% owner | 2 | 1 leg · 800,000 sh · $8,000,000 | — | 4 |
+6 more issuers among the filings shown — every filing appears in the table below.
Insider filings — Chen Bihua
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-02 | 4 | Corbus Pharmaceuticals Holdings, Inc. (CRBP) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP | Sale (S): 425,000 @ $4.10 | EDGAR |
| 2026-08-10 | 4 | BlossomHill Therapeutics, Inc. (BLSM) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP, Cormorant Private Healthcare Fund V LP, Cormorant Private Healthcare Fund VI, LP | Conversion (C): 1,599,993 · Conversion (C): 1,701,541 · Purchase (P): 312,500 @ $16 · Grant/award (A): 23,904 (derivative) @ $0 · Conversion (C): 1,599,993 (derivative) · Conversion (C): 1,701,541 (derivative) | EDGAR |
| 2026-07-06 | 4 | BridgeBio Oncology Therapeutics, Inc. (BBOT) | Other (J): 4,528,186 @ $0 · Other (J): 2,692,459 @ $0 · Other (J): 1,704,862 @ $0 · Other (J): 130,865 @ $0 | EDGAR |
| 2026-06-18 | 4 | BridgeBio Oncology Therapeutics, Inc. (BBOT) | Grant/award (A): 31,675 (derivative) @ $0 | EDGAR |
| 2026-04-30 | 4 | BRIGHT MINDS BIOSCIENCES INC. (DRUG) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP | Sale (S): 109,331 @ $89.50 | EDGAR |
| 2026-01-28 | 4/A | Helix Acquisition Corp. III (HLXC) jointly with Helix Holdings III LLC | Grant/award (A): 497,500 @ $10 · Purchase (P): 800,000 @ $10 · Other (J): 718,750 (derivative) | EDGAR |
| 2026-01-26 | 4 | Helix Acquisition Corp. III (HLXC) jointly with Helix Holdings III LLC | Grant/award (A): 497,500 @ $10 · Other (J): 718,750 (derivative) | EDGAR |
| 2025-12-15 | 4 | Corbus Pharmaceuticals Holdings, Inc. (CRBP) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP | Sale (S): 30,029 @ $11.46 | EDGAR |
| 2025-12-08 | 4 | EyePoint, Inc. (EYPT) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP | Sale (S): 60,000 @ $15.70 | EDGAR |
| 2025-10-01 | 4 | MoonLake Immunotherapeutics (MLTX) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund II, LP, Cormorant Private Healthcare Fund III LP, Cormorant Private Healthcare Fund IV LP | Sale (S): 70,748 @ $9.38 · Sale (S): 232,460 @ $8.40 · Sale (S): 3,390,943 @ $7.58 · Sale (S): 2,800,000 @ $6.61 · Sale (S): 5,827 @ $6.96 | EDGAR |
| 2025-08-13 | 4 | BridgeBio Oncology Therapeutics, Inc. (BBOT) | Option exercise (M): 4,172,126 · Disposition to issuer (D): 152,940 @ $0 · Grant/award (A): 760,496 @ $10.72 · Grant/award (A): 639,110 @ $10.72 · Grant/award (A): 5,598,425 @ $10.72 · Grant/award (A): 1,905,046 · +4 more | EDGAR |
| 2025-08-01 | 4 | Biomea Fusion, Inc. (BMEA) jointly with Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP, Cormorant Asset Management, LP | Holdings only — no transactions reported | EDGAR |
| 2025-06-13 | 4 | Biomea Fusion, Inc. (BMEA) jointly with Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP, Cormorant Asset Management, LP | Grant/award (A): 91,970 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | OnKure Therapeutics, Inc. (OKUR) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP, Cormorant Private Healthcare Fund IV LP, Cormorant Private Healthcare Fund V LP | Sale (S): 1,813,439 @ $1.85 | EDGAR |
| 2025-05-14 | 4 | OnKure Therapeutics, Inc. (OKUR) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP, Cormorant Private Healthcare Fund IV LP, Cormorant Private Healthcare Fund V LP | Sale (S): 24,300 @ $1.99 | EDGAR |
| 2025-02-19 | 4 | Aardvark Therapeutics, Inc. (AARD) jointly with Cormorant Asset Management, LP | Conversion (C): 800,189 · Purchase (P): 187,500 @ $16 · Conversion (C): 6,780,810 (derivative) | EDGAR |
| 2025-02-10 | 4 | Helix Acquisition Corp. II (HLXB) | Other (J): 30,000 (derivative) @ $0 | EDGAR |
| 2024-11-06 | 4 | BRIGHT MINDS BIOSCIENCES INC. (DRUG) jointly with Cormorant Asset Management, LP | Purchase (P): 184,331 @ $21.70 | EDGAR |
| 2024-10-17 | 4 | BRIGHT MINDS BIOSCIENCES INC. (DRUG) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP | Purchase (P): 238,097 @ $4.53 · Purchase (P): 63,173 @ $5.92 · Purchase (P): 33,343 @ $6.42 · Purchase (P): 8,900 @ $7.31 · Purchase (P): 2,600 @ $8.80 · Purchase (P): 2,700 @ $9.26 · +5 more | EDGAR |
| 2024-10-01 | 4 | BioAge Labs, Inc. (BIOA) jointly with Cormorant Asset Management, LP, Cormorant Private Healthcare Fund V LP, Cormorant Private Healthcare Fund IV LP | Conversion (C): 1,179,529 · Purchase (P): 450,000 @ $18 · Conversion (C): 5,263,772 (derivative) | EDGAR |
| 2024-09-24 | 4 | Corbus Pharmaceuticals Holdings, Inc. (CRBP) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP | Purchase (P): 45,085 @ $17.48 · Purchase (P): 25,943 @ $18.36 · Purchase (P): 66,088 @ $19.61 · Purchase (P): 139,551 @ $20.42 · Purchase (P): 47,564 @ $21.47 · Purchase (P): 25,769 @ $22.23 | EDGAR |
| 2024-06-13 | 4 | Biomea Fusion, Inc. (BMEA) jointly with Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP, Cormorant Asset Management, LP | Grant/award (A): 51,025 (derivative) @ $0 | EDGAR |
| 2024-05-08 | 4 | EyePoint Pharmaceuticals, Inc. (EYPT) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP | Purchase (P): 642,847 @ $11.70 · Purchase (P): 207,153 @ $12.36 | EDGAR |
| 2024-04-22 | 4 | EyePoint Pharmaceuticals, Inc. (EYPT) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP | Purchase (P): 395,244 @ $17.62 · Purchase (P): 186,521 @ $18.90 | EDGAR |
| 2024-04-03 | 4 | Immuneering Corp (IMRX) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP | Sale (S): 100 @ $3.07 · Sale (S): 300 @ $3.06 · Sale (S): 100 @ $3.05 · Sale (S): 600 @ $3.03 · Sale (S): 10 @ $3.01 · Sale (S): 10 @ $2.98 · +2 more | EDGAR |
| 2024-03-18 | 4 | Immuneering Corp (IMRX) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP | Sale (S): 345,266 @ $3.23 · Sale (S): 98,570 @ $4.25 · Sale (S): 54,215 @ $5.37 · Sale (S): 11,040 @ $5.97 · Sale (S): 400,000 @ $2.14 | EDGAR |
| 2024-03-11 | 4 | Corbus Pharmaceuticals Holdings, Inc. (CRBP) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP | Purchase (P): 46,799 @ $37.82 · Purchase (P): 10,736 @ $39.13 · Purchase (P): 90,325 @ $39.99 · Purchase (P): 102,140 @ $41.23 · Purchase (P): 29,342 @ $41.23 · Purchase (P): 24,983 @ $42.25 · +4 more | EDGAR |
| 2024-02-13 | 4 | Helix Acquisition Corp. II (HLXB) | Grant/award (A): 509,000 @ $10 · Purchase (P): 69,360 @ $10 · Purchase (P): 1,427,040 @ $10 · Purchase (P): 903,600 @ $10 | EDGAR |
| 2024-02-06 | 4 | Corbus Pharmaceuticals Holdings, Inc. (CRBP) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP | Purchase (P): 750,000 @ $19 | EDGAR |
| 2024-01-30 | 4 | Corbus Pharmaceuticals Holdings, Inc. (CRBP) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP | Purchase (P): 14,388 @ $25.73 · Purchase (P): 15,243 @ $26.66 · Purchase (P): 36,747 @ $27.70 · Purchase (P): 31,028 @ $28.82 · Purchase (P): 29,244 @ $29.42 · Purchase (P): 2,654 @ $31 · +8 more | EDGAR |
| 2024-01-11 | 4 | EyePoint Pharmaceuticals, Inc. (EYPT) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP | Purchase (P): 105,000 @ $21.32 · Purchase (P): 750,000 @ $19.75 | EDGAR |
| 2023-12-12 | 4 | EyePoint Pharmaceuticals, Inc. (EYPT) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP | Purchase (P): 588,235 @ $17 | EDGAR |
| 2023-12-06 | 4 | EyePoint Pharmaceuticals, Inc. (EYPT) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP | Purchase (P): 321,259 @ $18.80 · Purchase (P): 945,664 @ $19.88 · Purchase (P): 122,625 @ $20.62 · Purchase (P): 79,805 @ $21.87 · Purchase (P): 28,090 @ $22.80 · Purchase (P): 37,081 @ $24.01 · +11 more | EDGAR |
| 2023-10-25 | 4 | Ambrx Biopharma, Inc. (AMAM) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP | Purchase (P): 1,307,311 @ $6.99 | EDGAR |
| 2023-10-10 | 4 | MoonLake Immunotherapeutics (MLTX) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund II, LP, Cormorant Private Healthcare Fund III LP, Cormorant Private Healthcare Fund IV LP | Purchase (P): 58,839 @ $59.90 | EDGAR |
| 2023-10-04 | 4 | MoonLake Immunotherapeutics (MLTX) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund II, LP, Cormorant Private Healthcare Fund III LP, Cormorant Private Healthcare Fund IV LP | Purchase (P): 74,911 @ $57.37 · Purchase (P): 150,487 @ $57.25 · Purchase (P): 67,814 @ $57.32 | EDGAR |
| 2023-09-19 | 4 | Ambrx Biopharma Inc. (AMAM) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP | Purchase (P): 1,401,505 @ $9.05 · Purchase (P): 751,233 @ $9.24 | EDGAR |
| 2023-07-24 | 4 | GreenLight Biosciences Holdings, PBC (GRNA) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund II, LP | Sale (S): 9,188,659 @ $0 | EDGAR |
| 2023-07-05 | 4 | MoonLake Immunotherapeutics (MLTX) | Purchase (P): 800,000 @ $50 | EDGAR |
| 2023-06-28 | 4 | MoonLake Immunotherapeutics (MLTX) | Purchase (P): 1,481 @ $36.91 · Purchase (P): 3,755 @ $38.18 · Purchase (P): 10,593 @ $39.17 · Purchase (P): 38,623 @ $39.87 · Purchase (P): 50,642 @ $41.03 · Purchase (P): 61,042 @ $42.12 · +21 more | EDGAR |
| 2023-06-26 | 4 | Erasca, Inc. (ERAS) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund II, LP | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2023-06-16 | 4 | Biomea Fusion, Inc. (BMEA) jointly with Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP, Cormorant Asset Management, LP | Grant/award (A): 6,989 (derivative) @ $0 | EDGAR |
| 2023-04-20 | 4 | Ambrx Biopharma Inc. (AMAM) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP | Purchase (P): 3,376,646 @ $11.27 · Purchase (P): 951,909 @ $11.15 · Purchase (P): 886,634 @ $11.60 | EDGAR |
| 2023-04-17 | 4 | Ambrx Biopharma Inc. (AMAM) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP | Purchase (P): 1,193,808 @ $9.16 · Purchase (P): 841,967 @ $9.96 · Purchase (P): 562,121 @ $10.67 | EDGAR |
| 2023-04-03 | 4 | Biomea Fusion, Inc. (BMEA) jointly with Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP, Cormorant Asset Management, LP | Purchase (P): 400,000 @ $30 | EDGAR |
| 2023-03-22 | 4 | MoonLake Immunotherapeutics (MLTX) | Purchase (P): 446,881 @ $19.36 · Purchase (P): 63,700 @ $20.42 · Purchase (P): 78,008 @ $21.08 · Purchase (P): 238,511 @ $21.70 | EDGAR |
| 2023-03-16 | 4 | Ambrx Biopharma Inc. (AMAM) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP | Purchase (P): 250,000 @ $9.95 · Purchase (P): 250,000 @ $10.60 · Purchase (P): 500,000 @ $10.15 | EDGAR |
| 2022-12-21 | 4/A | Erasca, Inc. (ERAS) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund II, LP | Purchase (P): 307,692 @ $6.50 | EDGAR |
| 2022-12-20 | 4 | Erasca, Inc. (ERAS) jointly with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund II, LP | Purchase (P): 307,692 @ $6.50 | EDGAR |
| 2022-06-24 | 4 | Biomea Fusion, Inc. (BMEA) jointly with Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III LP, Cormorant Asset Management, LP | Grant/award (A): 23,867 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-20 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1599214 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs